Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant
Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a...
Saved in:
| Published in: | ACG case reports journal Vol. 11; no. 4; p. e01327 |
|---|---|
| Main Authors: | , , |
| Format: | Report |
| Language: | English |
| Published: |
01-04-2024
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Hepatitis B virus (HBV) reactivation can occur with the use of immunosuppressive therapy used to treat autoimmune conditions, such as rheumatoid arthritis. Janus kinase inhibitors, such as upadacitinib, have been approved for the treatment of rheumatoid arthritis. This is the first case report of a patient who used upadacitinib without antiviral prophylaxis against HBV and developed HBV reactivation, leading to fulminant hepatic failure necessitating emergent liver transplantation. |
|---|---|
| Bibliography: | ObjectType-Case Study-2 content type line 59 SourceType-Reports-1 ObjectType-Report-1 |
| ISSN: | 2326-3253 2326-3253 |
| DOI: | 10.14309/crj.0000000000001327 |